CYP2B6 and cardiac arrhythmia: Additionally, CYP2B6 slow metabolizers exhibit a reduced ability to metabolize S-methadone and were associated with an increased risk of a prolonged QT interval (OR = 4.5) [26], which may increase the risk of cardiac arrhythmias and sudden death.